SCHEMBL31728591

SCHEMBL31728591

COc1cc(-c2ccc(F)c(Cl)c2F)c2ncnc(N)c2c1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EIF2AK3 Q9NZJ5 6/20 0.39
▸ PDE5A O76074 1/20 0.39
▸ EPHB4 P54760 3/20 0.38
▸ SRC P12931 3/20 0.38
▸ ABL1 P00519 2/20 0.38
▸ EGFR P00533 2/20 0.38
▸ HCK P08631 2/20 0.38
▸ KDR P35968 2/20 0.38
▸ PIK3CB P42338 2/20 0.38
▸ MTOR P42345 2/20 0.38
▸ PIK3CG P48736 2/20 0.38
▸ PRKDC P78527 2/20 0.38
▸ PI4KB Q9UBF8 2/20 0.38
▸ PIK3CD O00329 1/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ FYN P06241 2/20 0.36
▸ GSK3B P49841 1/20 0.36
▸ TEC P42680 1/20 0.36
▸ BTK Q06187 1/20 0.36
▸ ITK Q08881 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31729173 0.92 CLK1 (0.35) EIF2AK3PDE5AEPHB4SRCABL1
SCHEMBL31728213 0.88 EIF2AK3 (0.38) EIF2AK3PDE5AEPHB4SRCABL1
SCHEMBL31729157 0.82 PDE5A (0.39) EIF2AK3PDE5AEPHB4SRCABL1
SCHEMBL31728133 0.81 CLK1 (0.36) EIF2AK3EPHB4SRCABL1EGFR
SCHEMBL31727792 0.81 PDCD1LG2 (0.36) EIF2AK3PDE5AEPHB4SRCABL1
SCHEMBL31727929 0.80 KHK (0.37) EIF2AK3PDE5AEPHB4SRCABL1
SCHEMBL31728714 0.80 FYN (0.39) EIF2AK3PDE5AEPHB4SRCABL1
SCHEMBL31728018 0.79 CLK1 (0.36) EIF2AK3EPHB4SRCABL1EGFR
SCHEMBL31729163 0.76 CLK1 (0.37) EPHB4SRCABL1EGFRHCK
SCHEMBL31728069 0.76 CLK1 (0.39) PI4KBCLK1MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235874-A1 HETEROCYCLICS AS EGFR INHIBITORS SCHRÖDINGER, INC. (US) 2025-11-13 — — WO disclosed
Send feedback